1-14 of 14
Gaia Schiavon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

John F.R. Robertson, Robert E. Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Anthony Skene, Daniel Rea, Samreen Ahmed, Ali Jahan, Kieran Horgan, Petra Rauchhaus, Roberta Littleford, S.Y. Amy Cheung, Marie Cullberg, Elza C. de Bruin, Loumpiana Koulai, Justin P.O. Lindemann, Martin Pass, Paul Rugman, Gaia Schiavon, Rahul Deb, Pauline Finlay, Andrew Foxley, Julia M.W. Gee
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5469.
https://doi.org/10.1158/1078-0432.CCR-22-3568
Published: 15 December 2022
View article titled, Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Open the PDF for Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) in another window
Journal Articles

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U. Budzar, John F.R. Robertson, William Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen R.D. Johnston, Stephen K. Chia
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (19): 5172–5177.
https://doi.org/10.1158/1078-0432.CCR-20-0224
Published: 01 October 2020
View article titled, <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Open the PDF for <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials in another window
Includes: Supplementary data
Journal Articles

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

John F.R. Robertson, Abigail Evans, Stephan Henschen, Cliona C. Kirwan, Ali Jahan, Laura M. Kenny, J. Michael Dixon, Peter Schmid, Ashutosh Kothari, Omar Mohamed, Peter A. Fasching, Kwok-Leung Cheung, Rachel Wuerstlein, Danielle Carroll, Teresa Klinowska, Justin P.O. Lindemann, Alexander MacDonald, Richard Mather, Rhiannon Maudsley, Michele Moschetta, Myria Nikolaou, Martine P. Roudier, Tinnu Sarvotham, Gaia Schiavon, Diansong Zhou, Li Zhou, Nadia Harbeck
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (16): 4242–4249.
https://doi.org/10.1158/1078-0432.CCR-19-3387
Published: 14 August 2020
View article titled, A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>−</sup> Primary Breast Cancer
Open the PDF for A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>−</sup> Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3947–3957.
https://doi.org/10.1158/1078-0432.CCR-19-3953
Published: 03 August 2020
View article titled, Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Open the PDF for Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H. Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S. Hirst, Alan Barnicle, Elza C. de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B. Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C. Turner, Cristina Saura, Barry R. Davies, Mafalda Oliveira, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3720–3731.
https://doi.org/10.1158/1078-0432.CCR-19-3324
Published: 15 July 2020
View article titled, Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Open the PDF for Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts in another window
Includes: Supplementary data
Journal Articles

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

John F.R. Robertson, Robert E. Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Anthony Skene, Daniel Rea, Samreen Ahmed, Ali Jahan, Kieran Horgan, Petra Rauchhaus, Roberta Littleford, S.Y. Amy Cheung, Marie Cullberg, Elza C. de Bruin, Loumpiana Koulai, Justin P.O. Lindemann, Martin Pass, Paul Rugman, Gaia Schiavon, Rahul Deb, Pauline Finlay, Andrew Foxley, Julia M.W. Gee
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1574–1585.
https://doi.org/10.1158/1078-0432.CCR-19-3053
Published: 01 April 2020
View article titled, Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Open the PDF for Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) in another window
Includes: Supplementary data
Journal Articles

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

Costanza Paoletti, Gaia Schiavon, Emily M. Dolce, Elizabeth P. Darga, T. Hedley Carr, Joseph Geradts, Matthias Hoch, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Shethah Morgan, Parul Patel, Vicky Rowlands, Nitharsan Sathiyayogan, Kimberly Aung, Erika Hamilton, Manish Patel, Anne Armstrong, Komal Jhaveri, Seock-Ah Im, Nadia Iqbal, Fouziah Butt, Caroline Dive, Elizabeth A. Harrington, J. Carl Barrett, Richard Baird, Daniel F. Hayes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (23): 5860–5872.
https://doi.org/10.1158/1078-0432.CCR-18-1569
Published: 03 December 2018
View article titled, Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial
Open the PDF for Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial in another window
Includes: Supplementary data
Journal Articles

The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer

Peter Barry, Alexandra Vatsiou, Inmaculada Spiteri, Daniel Nichol, George D. Cresswell, Ahmet Acar, Nicholas Trahearn, Sarah Hrebien, Isaac Garcia-Murillas, Kate Chkhaidze, Luca Ermini, Ian Said Huntingford, Hannah Cottom, Lila Zabaglo, Konrad Koelble, Saira Khalique, Jennifer E. Rusby, Francesca Muscara, Mitch Dowsett, Carlo C. Maley, Rachael Natrajan, Yinyin Yuan, Gaia Schiavon, Nicholas Turner, Andrea Sottoriva
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (19): 4763–4770.
https://doi.org/10.1158/1078-0432.CCR-17-3374
Published: 01 October 2018
View article titled, The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Open the PDF for The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

Erika P. Hamilton, Manish R. Patel, Anne C. Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah R. Morgan, Gaia Schiavon, Hazel M. Weir, Seock-Ah Im
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3510–3518.
https://doi.org/10.1158/1078-0432.CCR-17-3102
Published: 31 July 2018
View article titled, A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
Open the PDF for A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma J. Dean, J. Alejandro Pérez-Fidalgo, Gerald Batist, Philippe L. Bedard, Benoit You, Shannon N. Westin, Peter Kabos, Michelle D. Garrett, Mathew Tall, Helen Ambrose, J. Carl Barrett, T. Hedley Carr, S.Y. Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R. Davies, Elza C. de Bruin, Paul Elvin, Andrew Foxley, Peter Lawrence, Justin P.O. Lindemann, Rhiannon Maudsley, Martin Pass, Vicky Rowlands, Paul Rugman, Gaia Schiavon, James Yates, Jan H.M. Schellens
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (9): 2050–2059.
https://doi.org/10.1158/1078-0432.CCR-17-2260
Published: 30 April 2018
View article titled, A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <em>PIK3CA</em>-Mutated Breast and Gynecologic Cancers
Open the PDF for A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <em>PIK3CA</em>-Mutated Breast and Gynecologic Cancers in another window
Includes: Supplementary data
Journal Articles

Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR

Heidrun Gevensleben, Isaac Garcia-Murillas, Monika K. Graeser, Gaia Schiavon, Peter Osin, Marina Parton, Ian E. Smith, Alan Ashworth, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (12): 3276–3284.
https://doi.org/10.1158/1078-0432.CCR-12-3768
Published: 13 June 2013
View article titled, Noninvasive Detection of <em>HER2</em> Amplification with Plasma DNA Digital PCR
Open the PDF for Noninvasive Detection of <em>HER2</em> Amplification with Plasma DNA Digital PCR in another window
Includes: Supplementary data
Journal Articles

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Karel Eechoute, Martin N. Fransson, An K. Reyners, Floris A. de Jong, Alex Sparreboom, Winette T.A. van der Graaf, Lena E. Friberg, Gaia Schiavon, Erik A.C. Wiemer, Jaap Verweij, Walter J. Loos, Ron H.J. Mathijssen, Ugo De Giorgi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (20): 5780–5787.
https://doi.org/10.1158/1078-0432.CCR-12-0490
Published: 14 October 2012
View article titled, A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
Open the PDF for A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients in another window
Includes: Supplementary data
Journal Articles

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M. Franke, Gaia Schiavon, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer, Ron H.J. Mathijssen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 406–415.
https://doi.org/10.1158/1078-0432.CCR-10-2250
Published: 01 February 2011
View article titled, Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
Open the PDF for Drug Transporters and Imatinib Treatment: Implications for Clinical Practice in another window
Journal Articles

Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients

Daniele Santini, Bruno Vincenzi, Sara Galluzzo, Fabrizio Battistoni, Laura Rocci, Olga Venditti, Gaia Schiavon, Silvia Angeletti, Federica Uzzalli, Michele Caraglia, Giordano Dicuonzo, Giuseppe Tonini
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4482–4486.
https://doi.org/10.1158/1078-0432.CCR-07-0551
Published: 01 August 2007
View article titled, Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients
Open the PDF for Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients in another window